| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1048889293 |
| P356 | DOI | 10.1186/1475-2875-9-51 |
| P932 | PMC publication ID | 2833169 |
| P698 | PubMed publication ID | 20149249 |
| P5875 | ResearchGate publication ID | 41423660 |
| P50 | author | Diana Caridha | Q91612250 |
| Peter Wipf | Q29447250 | ||
| P2093 | author name string | Lucia Gerena | |
| Victor Melendez | |||
| Charlotte Lanteri | |||
| Norma Roncal | |||
| Jason Sousa | |||
| Erin Milner | |||
| Sean Gardner | |||
| Duane Goodine | |||
| Geoffrey Stuart Dow | |||
| Jayendra Bhonsle | |||
| Jose Cobar | |||
| William McCalmont | |||
| P2860 | cites work | Thermodynamics of partitioning of the antimalarial drug mefloquine in phospholipid bilayers and bulk solvents | Q74059904 |
| Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease | Q28190207 | ||
| Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives | Q28276286 | ||
| Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number | Q29615128 | ||
| Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique | Q29616826 | ||
| Drug-like properties and the causes of poor solubility and poor permeability | Q30660926 | ||
| Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum | Q33526131 | ||
| CNS drug design based on principles of blood-brain barrier transport | Q34066442 | ||
| Mefloquine induces dose-related neurological effects in a rat model | Q34509705 | ||
| Utility of alkylaminoquinolinyl methanols as new antimalarial drugs | Q35215427 | ||
| In silico prediction of blood–brain barrier permeation | Q35557423 | ||
| Mefloquine-induced disruption of calcium homeostasis in mammalian cells is similar to that induced by ionomycin | Q36424992 | ||
| The IPTi Consortium: research for policy and action | Q36483773 | ||
| Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki | Q37052790 | ||
| Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults | Q39392887 | ||
| In vitro activities of and mechanisms of resistance to antifol antimalarial drugs | Q39849631 | ||
| Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. | Q40476822 | ||
| Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. | Q40689125 | ||
| A nuclear magnetic resonance study of the interactions of the antimalarials chloroquine, quinacrine, quinine and mefloquine with dipalmitoylphosphatidylcholine bilayers | Q41945536 | ||
| Drug-free holidays: pre-travel versus during travel malaria chemoprophylaxis | Q47837595 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | malaria | Q12156 |
| P304 | page(s) | 51 | |
| P577 | publication date | 2010-02-11 | |
| P1433 | published in | Malaria Journal | Q15749954 |
| P1476 | title | Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols | |
| P478 | volume | 9 |
| Q41371247 | 4-Chloro-2,5-dimethyl-quinoline |
| Q34665879 | A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. |
| Q35081895 | Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice |
| Q38472391 | Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum |
| Q41920365 | Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations |
| Q41930137 | Differences in anti-malarial activity of 4-aminoalcohol quinoline enantiomers and investigation of the presumed underlying mechanism of action |
| Q33916111 | Expanding the Antimalarial Drug Arsenal-Now, But How? |
| Q37334397 | Exploring the scope of new arylamino alcohol derivatives: Synthesis, antimalarial evaluation, toxicological studies, and target exploration |
| Q39530026 | Imidazolopiperazines: hit to lead optimization of new antimalarial agents. |
| Q37979631 | Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics |
| Q34293304 | Mass administration of the antimalarial drug mefloquine to Guantánamo detainees: a critical analysis |
| Q38911151 | Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis |
| Q41928981 | New trifluoromethyl triazolopyrimidines as anti-Plasmodium falciparum agents. |
| Q57013585 | Other 4-Methanolquinolines, Amyl Alcohols and Phentathrenes: Mefloquine, Lumefantrine and Halofantrine |
| Q33654562 | Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria |
| Q38439588 | The use of a prodrug approach to minimize potential CNS exposure of next generation quinoline methanols while maintaining efficacy in in vivo animal models |
Search more.